Proton beam therapy for recurrent ovarian carcinoma: A case report

Kino, Tamina; Ando, Nobutoshi; Ogawara, Yuki; Shigeta, Hiroyuki

doi:10.1111/jog.14036

Cited by 2 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No case reports in gynecological cancer have reported severe complications related to PBT. Previous studies reported transient low-grade cystitis or fever only as complications [ 6 , 12 ]. A randomized phase IIB trial of esophageal cancer revealed that PBT was associated with fewer complications than intensity-modulated radiation therapy using conventional photons [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

“…Since 1954, when the medical use of protons was initially reported, PBT has been applied to various parts of the body, including the uvea, skull base, and spine [1,9,10]. In the gynecological field, the clinical use and efficacy of PBT have mainly been reported for cervical carcinoma [3][4][5], low-grade endometrial stromal sarcoma [11], and solitary recurrent epithelial ovarian cancer [12]. Only one case report of the vaginal recurrence of endometrial carcinoma treated with PBT is available in the literature, which describes the complete regression of the tumor; however, there was a complication of grade 1 cystitis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Proton beam therapy for the isolated recurrence of endometrial cancer in para-aortic lymph nodes: a case report

et al. 2022

View full text Add to dashboard Cite

Background Proton beam therapy penetrates tumor tissues with a highly concentrated dose. It is useful when normal structures are too proximate to the treatment target and, thus, may be damaged by surgery or conventional photon beam therapy. However, proton beam therapy has only been used to treat recurrent endometrial cancer in a few cases; therefore, its effectiveness remains unclear. Case presentation We herein report a case of the isolated recurrence of endometrial cancer in the para-aortic lymph nodes in a 59-year-old postmenopausal woman that was completely eradicated by proton beam therapy. The patient was diagnosed with stage IIIC2 endometrial cancer and treated with 6 courses of doxorubicin (45 mg/m2) and cisplatin (50 mg/m2) in adjuvant chemotherapy. Fifteen months after the initial therapy, the isolated recurrence of endometrial cancer was detected in the para-aortic lymph nodes. The site of recurrence was just under the left renal artery. Due to the potential risks associated with left kidney resection due to the limited surgical space between the tumor and left renal artery, proton beam therapy was administered instead of surgery or conventional photon beam therapy. Following proton beam therapy, the complete resolution of the recurrent lesion was confirmed. No serious complications occurred during or after treatment. There have been no signs of recurrence more than 7 years after treatment. Conclusions Proton beam therapy is a potentially effective modality for the treatment of recurrent endometrial cancer where the tumor site limits surgical interventions and the use of conventional photon beam therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Proton beam therapy for the isolated recurrence of endometrial cancer in para-aortic lymph nodes: a case report

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Additionally, antibody guided 90 Y has been explored in the context of ovarian cancer, but it did not proceed from phase III clinical trials ( 12 , 13 ). Alternative types of radiotherapy options that have been explored for ovarian cancer include proton beam therapy and carbon ion therapy with successful outcomes in two case reports of patients with recurrent ovarian cancer ( 14 , 15 ).…”

Section: Introductionmentioning

confidence: 99%

Intraperitoneal alpha therapy with 224Ra-labeled microparticles combined with chemotherapy in an ovarian cancer mouse model

et al. 2022

View full text Add to dashboard Cite

A novel alpha-therapy consisting of 224Ra-labeled calcium carbonate microparticles (224Ra-CaCO3-MP) has been designed to treat micrometastatic peritoneal disease via intraperitoneal (IP) administration. This preclinical study aimed to evaluate its efficacy and tolerability when given as a single treatment or in combination with standard of care chemotherapy regimens, in a syngeneic model of ovarian cancer in immune competent mice. Female C57BL/6 mice bearing ID8-fLuc ovarian cancer were treated with 224Ra-CaCO3-MP 1 day after IP tumor cell inoculation. The activity dosages of 224Ra ranged from 14 to 39 kBq/mouse. Additionally, 224Ra-CaCO3-MP treatment was followed by either carboplatin (80 mg/kg)-pegylated liposomal doxorubicin (PLD, 1.6 mg/kg) or carboplatin (60 mg/kg)-paclitaxel (10 mg/kg) on day 14 post tumor cell inoculation. All treatments were administered via IP injections. Readouts included survival, clinical signs, and body weight development over time. There was a slight therapeutic benefit after single treatment with 224Ra-CaCO3-MP compared to the vehicle control, with median survival ratios (MSRs) ranging between 1.1 and 1.3. The sequential administration of 224Ra-CaCO3-MP with either carboplatin-paclitaxel or carboplatin-PLD indicated a synergistic effect on overall survival at certain 224Ra activities. Moreover, the combinations tested appeared well tolerated in terms of weight assessment in the first 4 weeks after treatment. Overall, this research supports the further evaluation of 224Ra-CaCO3-MP in patients with ovarian cancer. However, the most optimal chemotherapy regimen to combine with 224Ra-CaCO3-MP should be identified to fully exploit its therapeutic potential.

show abstract

Proton beam therapy for recurrent ovarian carcinoma: A case report

Cited by 2 publications

References 14 publications

Proton beam therapy for the isolated recurrence of endometrial cancer in para-aortic lymph nodes: a case report

Proton beam therapy for the isolated recurrence of endometrial cancer in para-aortic lymph nodes: a case report

Intraperitoneal alpha therapy with 224Ra-labeled microparticles combined with chemotherapy in an ovarian cancer mouse model

Contact Info

Product

Resources

About